inVentiv Health Hires Senior Life Sciences Executive to Oversee Expansion of Multi-faceted Operations in India
Anita Tripathy Named President of inVentiv Health India
BURLINGTON, Mass. – November 25, 2013 – inVentiv Health, offering best-in-class clinical, commercial and consulting services to the biopharmaceutical industry, has named a senior executive in India’s life sciences industry to lead its expanding operations in India.
Anita Tripathy joins inVentiv Health from Capgemini, India, where she served on the leadership team of the global provider of consulting, technology and outsourcing services. At inVentiv Health, as President, India, she will be responsible for the management, development and growth of all business units in India across inVentiv’s Clinical and Commercial segments.
“By enhancing our organization in India and our service offerings there, inVentiv is prepared to better meet our customers’ need for more cost-effective research, data services and strategic outsourcing,” said Paul Meister, CEO of inVentiv Health. “India remains a top choice among global pharmaceutical and biotech companies on the skills-to-cost scale, and Anita’s deep understanding of India, IT and the life sciences sector will support our growth.”
India is a key market for inVentiv’s growth plans in Asia. With significant Indian operations already in place, the Company has an excellent platform for a new leader to expand both inVentiv’s customer base and the development of new services.
She will be based in Mumbai and report to inVentiv Health Executive Vice President Ray Hill.
At Capgemini, Anita Tripathy led a strategic cluster of IT products for the European market. While at Cognizant earlier in her career, she led the Strategic Business Unit for Life Sciences in India. She orchestrated teams based out of India, China and Argentina, delivering services across three continents, North America, Europe and Asia Pacific.
Before transitioning to the life sciences industry, she worked in ERP applications for KPIT Cummins Infosystems Ltd., and at Satyam Computer Services Ltd. She also worked in Pune at Nestle India as a systems analyst, and at ICIM Ltd as a senior systems engineer.
She holds a Bachelor’s degree in Chemistry from Berhampur University and a Master’s in Computer Applications from the Regional Engineering College, Rourkela, Orissa, India.
About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv’s 12,000 employees help more than 550 clients rapidly transform promising ideas into commercial reality. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inVentivHealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of our acquisition of Catalina Health Resource, LLC and any future acquisitions; the impact of any change in our current credit ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact on pharmaceutical manufacturers, including pricing pressures, from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth, including through outsourced service providers; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base, including the impact of the final HIPAA Privacy Rule on the willingness of pharmaceutical manufacturers to sponsor patient adherence programs; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.